Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2025 | PSMAddition: 177Lu-PSMA-617 plus ADT and ARPI in PSMA-positive mHSPC

Scott Tagawa • 19 Oct 2025
ESMO 2025
Genitourinary Cancer Prostate Cancer 177Lu-PSMA-617
PSMAddition

Scott Tagawa, MD, MS, FACP, Weill Cornell Medical Center, New York, NY, discusses the Phase III PSMAddition trial (NCT04720157), which evaluated [177Lu]Lu-PSMA-617 in combination with androgen deprivation therapy (ADT) and an androgen receptor pathway inhibitor (ARPI) in patients with PSMA-positive metastatic hormone-sensitive prostate cancer. The addition of 177Lu-PSMA-617 significantly improved radiographic progression-free survival, with a favorable trend in overall survival, manageable safety profile, and no meaningful impact on quality of life. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Scott Tagawa

Evaluating adverse events related to 177Lu-PSMA-617 in PSMA-positive mHSPC
0:53
Evaluating adverse events related to 177Lu-PSMA-617 in PSMA-positive mHSPC
Scott Tagawa • 19 Oct 2025
Challenges in identifying patients suited for PSMA-targeted therapies in HSPC
1:24
Challenges in identifying patients suited for PSMA-targeted therapies in HSPC
Scott Tagawa • 19 Oct 2025
Dose-escalation and expansion study of 225Ac-J591 in mCRPC
2:47
Dose-escalation and expansion study of 225Ac-J591 in mCRPC
Scott Tagawa • 19 Oct 2025
Key findings from Phase I/II Study: fractionated Lu-177 PSMA therapy shows safety and promise
0:29
Key findings from Phase I/II Study: fractionated Lu-177 PSMA therapy shows safety and promise
Scott Tagawa • 3 Jun 2024

Related Videos

Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
2:10
Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
Tian Zhang • 1 Jun 2026
Highlights in ADCs for bladder cancer at ASCO 2026
1:29
Highlights in ADCs for bladder cancer at ASCO 2026
Tian Zhang • 1 Jun 2026
EV plus pembrolizumab improves perioperative outcomes in muscle-invasive bladder cancer
3:36
EV plus pembrolizumab improves perioperative outcomes in muscle-invasive bladder cancer
Tian Zhang • 1 Jun 2026
Drug repurposing and trial challenges in rare renal medullary carcinoma
3:11
Drug repurposing and trial challenges in rare renal medullary carcinoma
Pavlos Msaouel • 30 May 2026
The content of VJOncology is intended for healthcare professionals